United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The pharma giant is setting itself up for success, although a little luck also helps.

Pfizer Has Gotten Better at Developing Drugs. Here's Why

BioNTech SE

The FDA has accepted  Pfizer Inc's (NYSE: PFE) marketing application seeking approval for TicoVac under priority review status. TicoVac is the tick-borne encephalitis (TBE) vaccine for active immunization in individuals aged one and older.

Pfizer's Tick-Borne Encephalitis Vaccine Gets Priority Review Tag In US

Johnson & Johnson

Moderna

Pfizer Inc. (NYSE: PFE), Moderna Inc. (Nasdaq: MRNA) and Johnson & Johnson (NYSE: JNJ) said they are committed to making a total of 240 million doses of COVID-19 vaccines available in the U.S. by the end of March. What Happened: The drug makers told a House subcommittee on Tuesday they are working on ramping up production of their vaccines to meet demand.

Pfizer, Moderna, J&J Pledge To Make 240M COVID-19 Vaccine Doses Available In US By March-End

Eli Lilly

Merck

Even investors that don't own the stocks must have had their interest piqued about the goings-on with GameStop Corp. (NYSE:GME), AMC Entertainment Holdings Inc. (NYSE:AMC) and Express Inc. (NYSE:EXPR). The companies were involved in a "short squeeze" that saw the shares of all three struggling companies gyrating wildly.

Big Pharma Short Percentage Is Below Overall Market

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review the company's Biologics License Application (BLA) for TicoVac™, its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals 1 year of age and older.1,2 If approved, TicoVac would be the first vaccine in the U.S. to help protect adults and children who are visiting or living in TBE endemic areas. In line with Priority

U.S. FDA Accepts for Priority Review Pfizer's Application for TicoVac™ (Tick-borne Encephalitis Vaccine)

Pfizer and Moderna said Tuesday they're making improvements that will allow them to deliver more vaccines in the coming months.

Pfizer And Moderna To Dramatically Increase Covid-19 Vaccine Production This Spring

Last week, there were two positive developments relating to Pfizer and its German partner BioNTech's Covid-19 vaccine, and one possible negative development. Firstly, Pfizer says based on internal testing that its vaccine can tolerate warmer temperatures than initially specified, possibly making.

Pfizer Vaccine Updates: Possibly Easier Storage, Efficacy Against South African Strain

Regeneron Pharmaceuticals

The FDA encourages companies to evaluate the impact of COVID-19 virus variants on the efficacy or performance of their COVID-19 vaccines, tests and medicines.

FDA Issues New Guidelines for COVID-19 Vaccines, Tests, Drugs

There are two main reasons. At least one of them, though, isn't a problem anymore.

Why Has Pfizer Stock Floundered?

2 Reasons Pfizer's COVID Vaccine Prospects Just Got Even Better

Bank of America

Disney

NIKE

PepsiCo

Procter & Gamble

When starting out, it's probably best to look at quality. Here are seven familiar names for new investors to consider.

7 of the Best Stocks To Buy as a New Investor

“We should be very encouraged by these initial findings,” said the head of Public Health England.

Pfizer Vaccine Highly Effective After Just One Dose, U.K. Early Data Suggest

Investing in dividend growth stocks is one of the most famous strategies today, but unfortunately, finding lucrative opportunities has become increasingly difficult as a result of the record bull run. Stock prices of many renowned dividend-paying companies have appreciated double or triple digits since last March, and this calls for extreme caution from investors whose objective is to generate a safe and steady income stream by investing in stocks.

Pfizer Inc: An Undervalued Dividend Growth Stock

Pfizer: An Undervalued Dividend Growth Stock

An initial dose of the vaccine made by Pfizer and BioNTech cuts the risk of coronavirus infection, Public Health England announced on Monday as U.K. Prime Minister Boris Johnson confirmed plans to relax lockdown rules.

Pfizer vaccine reduces coronavirus-infection risk, Public Health England says

The Israel health ministry said that Pfizer Inc (NYSE: PFE) and BioNtech SE's (NASDAQ: BNTX) COVID-19 vaccine had proved 95.8% effective in preventing coronavirus infection among those vaccinated two weeks after receiving their second shot, compared to unvaccinated people, according to data compiled up to February 13. The shot appeared to stop the vast majority of vaccine recipients in Israel from COVID-19 infection, providing the first real-world indication that the immunization will curb transmission of the coronavirus, the health ministry reported.

Pfizer/BioNtech's COVID-19 Shot Staved Off Illness, Death For Over 95% Of Israeli patients

The U.S. President Joe Biden met with Pfizer Inc's (NYSE: PFE) CEO Albert Bourla on Friday to discuss its COVID-19 vaccine stockpile estimated to be ready by Summer 2021, Bloomberg reports. The meeting took place at Pfizer's manufacturing facility in Michigan.

Pfizer Expands Production For COVID-19 Doses After Meeting With President: Bloomberg

You should definitely follow Buffett in one way.

Warren Buffett Just Sold His Pfizer Stock. Should You?

That's good news for the rest of the world.

Pfizer's Covid Vaccine Over 95% Effective In Israel, New Study Reportedly Shows

The new findings promise simpler transport, storage, and administration for BNT162b2.

Pfizer and BioNTech Coronavirus Vaccine Effective After 1 Dose, Can Last 2 Weeks in Standard Freezer, Separate Research Shows

Kraft Heinz

Citigroup

Lumen Technologies

On Tuesday, Feb. 16, the SEC released filings from many high-profile investors such as Warren Buffett, Cathie Wood and Michael Burry. Burry, of "The Big Short" fame, had GameStop as his biggest holding in June when the stock was at only $4.

Michael Burry's Top 5 Holdings: Pfizer, CitiGroup, Kraft Heinz, More

Pfizer and BioNTech announced Friday that they are seeking approval from the US Food and Drug Administration to store their COVID-19 vaccine at higher temperatures. New data from Pfizer shows the shots can be stored at temperatures between minus 13 degrees and 5 degrees Fahrenheit for up to two weeks as an "alternative or complement to storage in an ultra-low temperature freezer." Pfizer CEO Albert Bourla in a press release said, "We appreciate our ongoing collaboration with the FDA and CDC as we work to ensure our vaccine can be shipped and stored under increasingly flexible conditions. If approved, this new storage option would offer pharmacies and vaccination centers greater flexibility in how they manage their vaccine supply."

Promising new data shows Pfizer's vaccine can overcome its ultra-cold storage requirements, as new research hints at just how effective the shot is (PFE)

Enterprise Products Partners

PIMCO Dynamic Income Fund

Palantir Technologies

Unity Software

Growth stocks continue to outpace value stocks by a wide margin, and market valuation metrics are increasingly very high.

Massive Growth Bubble: 5 Attractive Stocks To Buy Now

Pfizer's numbers alone can be deceptive. That's why we took a deep dive into the company's trends and insights into its future.

A Closer Look At The Numbers: Pfizer Administers A Dose Of Neutrality

Pfizer (PFE) and BioNTech begin dosing in a mid-to-late-stage study on their COVID-19 vaccine in healthy pregnant women.

News for Pfizer Stock (PFE)